Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy-Reference-Cited by-同舟云学术

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

Published:2017-07-12 Issue:2 Volume:32 Page:353-363
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Yao Z,Deng L,Xu-Monette Z Y,Manyam G C,Jain P,Tzankov A,Visco C,Bhagat G,Wang J,Dybkaer K,Tam W,Hsi E D,van Krieken J H,Ponzoni M,Ferreri A J M,Møller M B,Winter J N,Piris M A,Fayad L,Liu Y,Song Y,Orlowski R Z,Kantarjian H,Medeiros L J,Li Y,Cortes J,Young K H

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017222.pdf

Reference47 articles.

1. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12: 1013–1022.

2. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040–2045.

3. Vaidya R, Witzig TE . Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann oncol 2014; 25: 2124–2133.

4. Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007; 110: 1278–1282.

5. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S . The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur j haematol 2006; 76: 473–480.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of Diffuse Large B Cell Lymphoma With Rapidly Developing Abdominal Distension As the Only First Clinical Presentation;Cureus;2024-07-18

2. Utility of leukocyte‐associated immunoglobulin‐like receptor‐1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B‐cell non‐Hodgkin lymphoma;Cytometry Part B: Clinical Cytometry;2024-06-21

3. Comparative Review of the Current and Future Strategies to Evaluate Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma Diagnosis;Diagnostics;2024-03-21

4. Pre-treatment [ ¹⁸ F]FDG PET/CT for assessing bone marrow involvement and prognosis in patients with newly diagnosed peripheral T-cell lymphoma;Hematology;2024-03-11

5. Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre ¹⁸F-FDG PET/CT and bone marrow biopsy evaluation study;Radiology and Oncology;2024-02-21